Prostate enucleation using a holmium laser, known as HoLEP, relieves urinary symptoms and improves quality of life to a similar degree as standard surgery in the first year, cochrane.org reported. However, HoLEP substantially reduces the need for blood transfusions compared to traditional procedures.
Benign prostatic hyperplasia is a non-cancerous condition where the prostate gland grows larger as men age, gradually blocking the flow of urine through the urethra.
To treat this urinary obstruction, surgeons have long relied on transurethral resection of the prostate, or TURP, which involves scraping away extra tissue with a specialized instrument inserted through the penis. Newer techniques employ lasers to remove or destroy the enlarged tissue, offering alternative approaches for patients.
A comprehensive review published by cochrane.org examined 52 studies involving 6,242 men to evaluate how HoLEP compares with other surgical options. The analysis focused primarily on comparisons between HoLEP and standard TURP during the first year after the operation, capturing patient outcomes across 11 countries where average participant ages ranged from 65 to 74 years.
Improving Urinary Flow and Quality of Life
- Similar Symptom Relief: HoLEP and traditional TURP provide comparable improvements in urinary flow and overall quality of life within the first year.
- Lower Bleeding Risk: Patients undergoing HoLEP face a significantly lower likelihood of requiring a blood transfusion than those undergoing standard surgical resection.
- Ejaculatory Impact: While standard operations often lead to retrograde ejaculation, clinical trials reviewed to date have largely omitted detailed reporting on this specific functional outcome.
Symptom Relief and Transfusion Rates
Data from 14 studies involving 1,666 people showed that HoLEP relieves urinary symptoms to an extent very similar to TURP, with any observed differences deemed too small to matter clinically. Quality of life measures evaluated across six studies with 876 participants yielded matching conclusions, demonstrating equivalent patient satisfaction between the two methods. Rates of serious complications, repeat surgeries, and erectile function preservation appeared comparable during the initial 12-month window.
The most pronounced operational advantage of the holmium laser technique centers on hemostasis, or the control of bleeding. According to cochrane.org, HoLEP probably lowers the chance of needing a blood transfusion compared to most other prostate surgeries. Approximately 44 in every 1,000 men require a transfusion after TURP, whereas only about 8 in every 1,000 men need one following HoLEP, based on findings from 15 studies encompassing 1,755 patients.
| Procedures Compared | Transfusion Rate per 1,000 Men | Primary Clinical Outcome |
|---|---|---|
| Standard TURP | About 44 men | Established standard; higher bleeding risk |
| Holmium Laser Enucleation (HoLEP) | About 8 men | Equivalent symptom relief; lower transfusion risk |
Unresolved Questions and Evidence Limits
Despite the large volume of comparative data, researchers lack knowledge regarding long-term trajectories and specific patient cohorts. Most of the evaluated studies followed participants for only 12 months, leaving the durability of HoLEP benefits over multi-year periods unconfirmed by the current literature. Trial designs also faced inherent blinding challenges, as it is impossible to conceal the surgical method from operating physicians and difficult to mask patients.
Surgeon proficiency also introduces variability into clinical outcomes, as complication rates tend to decline steadily until operators surpass roughly 350 completed procedures. Finally, researchers were unable to perform planned analyses for individuals with very large prostates measuring 80 milliliters or greater, nor for patients taking routine blood-thinning medications. These specific demographic groups represent the clinical populations where holmium laser enucleation might offer the most pronounced advantages, which necessitates targeted future investigations.
Contraindications & When to Consult a Doctor
The underlying review evaluated by this report remains current up to April 8, 2026.
References
- Cochrane Database of Systematic Reviews – Holmium laser enucleation of the prostate (HoLEP) versus other surgical methods for treating benign prostatic hyperplasia.
